A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Condition: Relapsed or Refractory Acute Lymphoblastic Leukemia Intervention: Biological: single dose of CNCT19 Sponsor: Juventas Cell Therapy Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials